CONMED (CNMD) Q3 2024 earnings summary

Executive summary

• Q3 2024 sales reached $316.7 million, up 4.0% year-over-year as reported and 4.3% in constant currency, driven by growth in both orthopedic and general surgery product lines.

• Net income for Q3 2024 was $49.0 million, up from $15.8 million in Q3 2023, reflecting improved margins and lower operating expenses.

• Adjusted diluted EPS was $1.05, a 16.7% increase year-over-year; GAAP diluted EPS was $1.57, up from $0.50 in Q3 2023.

• Leadership transition announced: Pat Beyer to succeed Curt Hartman as CEO effective January 1, 2025.

• Operations were temporarily disrupted by hurricanes Helene and Milton, impacting employees, facilities, and customers in the Southeast.

Financial highlights

• Q3 2024 net sales: $316.7 million, up 4.0% year-over-year; nine months: $961.1 million, up 4.7%.

• Gross profit margin improved to 56.5% in Q3 2024, up from 55.2% in Q3 2023.

• Operating income for Q3 2024 was $65.7 million (20.7% of sales), up from $30.3 million (9.9%) in Q3 2023.

• Cash flow from operations was $51.2 million in Q3 and $123.6 million for the first nine months, up from $46.1 million and $69.0 million a year ago.

• Single-use products accounted for 86% of Q3 revenue and grew 6.9% year-over-year, while capital products declined 10.6%.

Outlook and guidance

• Q4 2024 revenue expected between $339 million and $344 million, representing 4% to 5% year-over-year growth.

• Full-year 2024 revenue guidance set at $1.300–$1.305 billion, with non-GAAP EPS guidance raised to $4.00–$4.05, up 16% to 17% year-over-year.

• Q4 adjusted EPS projected at $1.18–$1.23; foreign currency impact expected to be immaterial.

• Management expects continued inflationary and supply chain pressures through 2024.